Literature DB >> 16357314

18F-choline images murine atherosclerotic plaques ex vivo.

Christian M Matter1, Matthias T Wyss, Patricia Meier, Nicolas Späth, Tobias von Lukowicz, Christine Lohmann, Bruno Weber, Ana Ramirez de Molina, Juan Carlos Lacal, Simon M Ametamey, Gustav K von Schulthess, Thomas F Lüscher, Philipp A Kaufmann, Alfred Buck.   

Abstract

OBJECTIVE: Current imaging modalities of atherosclerosis mainly visualize plaque morphology. Valuable insight into plaque biology was achieved by visualizing enhanced metabolism in plaque-derived macrophages using 18F-fluorodeoxyglucose (18F-FDG). Similarly, enhanced uptake of 18F-fluorocholine (18F-FCH) was associated with macrophages surrounding an abscess. As macrophages are important determinants of plaque vulnerability, we tested 18F-FCH for plaque imaging. METHODS AND
RESULTS: We injected 18F-FCH (n=5) or 18F-FDG (n=5) intravenously into atherosclerotic apolipoprotein E-deficient mice. En face measurements of aortae isolated 20 minutes after 18F-FCH injections demonstrated an excellent correlation between fat stainings and autoradiographies (r=0.842, P<0.0001), achieving a sensitivity of 84% to detect plaques by 18F-FCH. In contrast, radiotracer uptake 20 minutes after 18F-FDG injections correlated less with en face fat stainings (r=0.261, P<0.05), reaching a sensitivity of 64%. Histological analyses of cross-sections 20 minutes after coinjections of 18F-FCH and 14C-FDG (n=3) showed that 18F-FCH uptake correlated better with fat staining (r=0.740, P<0.0001) and macrophage-positive areas (r=0.740, P<0.0001) than 14C-FDG (fat: r=0.236, P=0.29 and CD68 staining: r=0.352, P=0.11), respectively.
CONCLUSIONS: 18F-FCH identifies murine plaques better than 18F-FDG using ex vivo imaging. Enhanced 18F-FCH uptake into macrophages may render this tracer a promising candidate for imaging plaques in patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357314     DOI: 10.1161/01.ATV.0000200106.34016.18

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  41 in total

Review 1.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.

Authors:  Thibaut Quillard; Peter Libby
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

Review 2.  Advances in detection and characterization of atherosclerosis using contrast agents targeting the macrophage.

Authors:  Michael J Lipinski; Juan Carlos Frias; Zahi A Fayad
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 3.  Recent advances in metabolic imaging.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

4.  Noninvasive Positron Emission Tomography Imaging of Coronary Arterial Inflammation.

Authors:  Amr Abdelbaky; Ahmed Tawakol
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-01

Review 5.  Imaging of atherosclerosis.

Authors:  D R J Owen; A C Lindsay; R P Choudhury; Z A Fayad
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 6.  The year in molecular imaging.

Authors:  Eric A Osborn; Farouc A Jaffer
Journal:  JACC Cardiovasc Imaging       Date:  2012-03

7.  Progress in atherosclerotic plaque imaging.

Authors:  Giulia Soloperto; Sergio Casciaro
Journal:  World J Radiol       Date:  2012-08-28

8.  Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques.

Authors:  Hui Liu; Hongjun Jin; Junbin Han; Xuyi Yue; Hao Yang; Mohamed A Zayed; Robert J Gropler; Zhude Tu
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

Review 9.  Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview.

Authors:  L M Riou; A Broisat; J Dimastromatteo; G Pons; D Fagret; C Ghezzi
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 10.  Imaging of the unstable plaque: how far have we got?

Authors:  Christian M Matter; Matthias Stuber; Matthias Nahrendorf
Journal:  Eur Heart J       Date:  2009-10-15       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.